Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals

Area of Science:

• Pharmaceutical Chemistry
• Toxicology
• Regulatory Science

Background:

• N-Nitrosamines are potent mutagens and probable human carcinogens.
• Nitrosamine impurities, like NDMA in valsartan, raised global regulatory concern in 2018.
• Regulatory bodies collaborate to mitigate patient exposure to these drug impurities.

Purpose of the Study:

• To provide scientific insights into nitrosamine impurity risks and origins.
• To recommend strategies for controlling and reducing nitrosamine impurities in pharmaceuticals.

Main Methods:

• Review of scientific literature on nitrosamine formation.
• Analysis of regulatory communications and quality control data.
• Synthesis of information on risk factors and mitigation approaches.

Main Results:

• Identified key risk factors and potential root causes for nitrosamine formation in drug products.
• Outlined current scientific understanding of nitrosamine impurity profiles.
• Provided actionable recommendations for risk management.

Conclusions:

• Effective control of nitrosamine impurities requires a comprehensive quality-by-design approach.
• Ongoing collaboration and information sharing are crucial for regulatory convergence and patient safety.
• Proactive risk assessment and mitigation are essential to prevent nitrosamine contamination in pharmaceuticals.